Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS5461 in Subjects With Renal Impairment

NCT02508506 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT02508506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02508506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS5461 in Subjects With Renal Impairment
Lead sponsor
Alkermes, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2015
Completion date
December 31, 2015
Enrollment
22 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment